With Bayer "badly broken in four places," now is not the right time to consider offloading its Consumer Health business, according to group CEO Bill Anderson. Bayer must focus its full attention for the next few years on addressing challenges which include mounting debt and costly litigation before a change to the company's structure can be considered.
Breaking up is hard to do, for Bayer at least. As it watches its biggest OTC rivals go solo, Bayer has decided to hold onto its Consumer Health business.
A six-month long strategic review led CEO Bill Anderson to conclude that offloading Consumer Health right now won’t solve the
A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.
Amazon executive moves Hims & Hers; INW Manufacturing adds IPA board member as CSO; USC Gerontology School dean joins Niagen advisory board; ‘Be You, NOW’ campaign during Women’s Health Month; direct seller Tranont expands advisory board; Vitamin Shoppe, sports nutrition brands support Team Red, White & Blue cross-US runners; and Powerade supports Morgan's Message.
C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.
